Today’s Premarket Trade Brief — May 5, 2026 (Tuesday)
*A plain-English summary of our top setups before the bell.*
---
## The big picture
Yesterday was thin (one true high-conviction trade: RDDT). Today is the **opposite — six high-conviction signals before the open**, ranging from a biotech Phase 3 success to multiple Q1 earnings blowouts. This is the richest catalyst day in over a week.
The market is sorting through three different stories at once:
1. **Phase 3 clinical wins** that crystallize a regulatory path (VRDN today)
2. **Q1 earnings blowouts** with raised guidance (STRL, DOCN, PINS)
3. **AI-cloud rotation** still picking up institutional flow (DOCN’s $120M AI ARR is the latest data point)
The volume is showing up. Every one of our six picks crossed the institutional-volume threshold by 9:14 AM. That’s institutional money voting with their feet *before* the open — which historically translates to follow-through during the regular session.
---
## #1 — Viridian (VRDN): The cleanest trade of the day
**What happened:** This morning, Viridian announced positive Phase 3 results from REVEAL-2 — its **second** pivotal Phase 3 trial of elegrobart, a once-every-4-or-8-weeks injection for Thyroid Eye Disease. The drug hit its primary endpoint with **50-54% of patients responding versus 15% on placebo**.
**Why this matters:** Phase 3 trials fail roughly half the time. Hitting Phase 3 is the highest hurdle in drug development — it means the drug is real medicine, not just a hypothesis. And this is the *second* Phase 3 success — REVEAL-1 hit earlier. Two for two.
**The kicker:** Viridian plans to file with the FDA in **Q1 2027** — about 9 months away. That’s a clear, dated regulatory path. If approved, elegrobart would be an at-home subcutaneous treatment competing in a billion-dollar market currently dominated by Tepezza (an IV infusion).
**Volume confirmation:** The stock is up **35% premarket on 34x normal volume**, and importantly, it’s *up another 39% from today’s open* — meaning every buyer who bought the open is currently making money. This is pure accumulation, no profit-taking visible.
**This is the highest-conviction trade on the board today.** Phase 3 wins with regulatory paths typically run for days to weeks, not hours. Position sizing matters — biotech can be volatile — but the setup quality is as clean as it gets.
---
## #2 — Sterling Infrastructure (STRL): The data-center boom in earnings form
Sterling makes earthwork and concrete for industrial sites — including the foundations under data centers. They reported Q1 earnings this morning that were a complete **blowout**:
- Revenue up **91.6% year-over-year** to $825 million (vs. $604M expected)
- Earnings of $3.59 vs. $2.29 expected (a **57% beat**)
- They **raised their full-year guidance** to $18.40-19.05 EPS — well above what Wall Street was modeling
**The narrative:** Every AI data center being built right now needs site preparation, concrete, civil engineering. Sterling’s order book reflects the buildout cycle. They’re an unsexy way to play the AI infrastructure boom — and at this point, possibly the cleanest one fundamentally.
**Volume note:** The institutional-volume threshold just crossed — 2.06x normal pre-market volume. That’s the green light we wait for. Earlier this morning the volume was just under it; institutions arrived right before the open.
**Watch:** Stock is up 30% pre-market at $688. The challenge is whether it holds the gap into the close. With a raised full-year guide, large fund managers tend to add over multiple sessions rather than chase Day 1. Day 2 follow-through is often where the real money is made.
---
## #3 — DigitalOcean (DOCN): AI-cloud growth + a squeeze setup
DigitalOcean is the small-business alternative to AWS — and they reported Q1 earnings that hit two important notes:
- **EPS of $0.44 versus $0.26 expected** — a 67% beat, biggest of the day
- **AI customer revenue grew 150% year-over-year** — their “Agentic Inference Cloud” is finding genuine traction with AI-native startups
**The setup that makes this special:** DOCN has a 15.79% short interest with the stock now up 19% premarket on confirmed institutional volume. **That’s the textbook short-squeeze setup**. When shorts are this heavy and a stock breaks higher on real volume, shorts have to buy to cover — which adds to the upside.
**Why we’re watching the open:** Shorts often try to fade gap-ups in the first 15 minutes. If DOCN holds the open green for an hour, the squeeze mechanics kick in. If shorts succeed in pushing it red, the squeeze gets postponed.
**Trade idea:** Watch the first 30 minutes for direction. Don’t enter pre-market — let the gap test resolve, then enter on the first higher-low.
---
## #4 — Edgewise Therapeutics (EWTX): The other biotech catalyst
Edgewise reported new data on **EDG-7500**, an oral pill for hypertrophic cardiomyopathy (HCM) — a heart muscle disease that causes the walls of the left ventricle to thicken. Their Phase 2 Part D efficacy data appears to be the catalyst, with the Phase 3 trial design moving forward for an end-of-2026 launch.
**The competitive landscape matters:** HCM already has a $13B+ blockbuster in Bristol Myers Squibb’s Camzyos, and Cytokinetics’ aficamten is in late stages. Edgewise is claiming a **novel mechanism** (cardiac sarcomere modulator vs. myosin inhibitor) — which, if it holds up, could differentiate clinically.
**The risk note:** Phase 2 in established competitive classes can fade after the initial pop (we’ve seen this pattern before). However, Phase 2 *Part D* (later stage) with positive efficacy and an announced Phase 3 design is more durable than early Phase 2. So far volume is confirming — 4.3x normal.
**Watch:** The first 30 minutes determine whether this is a Day 1 momentum trade or fades back toward $36-37.
---
## #5 — Pinterest (PINS): The first $1 billion quarter
Pinterest crossed a milestone today — **first quarter ever above $1 billion in revenue**. The full report:
- Revenue $1.01B vs. $965M expected — **18% YoY growth**
- EPS $0.27 vs. $0.23 expected (17% beat)
- Monthly active users hit a **record 631 million** (up 11%, tenth straight quarter of double-digit user growth)
- Q2 revenue guidance raised to $1.13-1.15B
- **$2 billion share buyback** announced
**The narrative:** Pinterest is the quietly winning story in social media — they’ve turned around their advertising business with AI personalization, kept user growth strong, and the buyback says management thinks the stock is cheap.
**Why this is a more conservative trade than VRDN/STRL:** It’s a $14B mega-cap that’s already up 17% premarket. The big move likely happened pre-market. But for traders who want a “cleaner” earnings beat with less binary risk, PINS is a slower, steadier setup.
---
## #6 — Cytokinetics (CYTK): Tonight’s binary catalyst
Cytokinetics is up 22% pre-market on **insane volume — 33x normal** — but here’s the thing: **they haven’t reported earnings yet**. They report tonight at 4:00 PM ET.
This is pre-earnings positioning. The volume is institutional money lining up for what they expect to be a strong report. There are two reasons for the excitement:
1. **MYQORZO (aficamten) — their HCM drug — was FDA-approved late last year.** Tonight will be the **first quarter where they report MYQORZO sales numbers**. The market is betting on a strong launch.
2. **Aficamten Phase 3 results** for hypertrophic cardiomyopathy are expected in Q2 2026.
**Why we’re cautious:** Pre-earnings runs of 22% can result in “good but not great” disappointment. The bar is now **HIGH** — they need to crush, not just beat. Same dynamic as PLTR yesterday (which we correctly flagged would gap-and-fade on a modest beat).
**Trade idea:** Don’t enter ahead of earnings. Watch the after-hours reaction tonight. If they gap up *another* 5-10% on real numbers, that’s the entry. If they gap down -5% on “in line” results, the pre-earnings positioning was the trade and it’s already over.
---
## The off-screener play: Reddit (RDDT) — Day 4 R10.1 entry forming
We’ve been watching RDDT for an entry since their earnings on April 30. Yesterday we predicted: *”Wait for Tue/Wed (Day 4-5) flat-zone consolidation around current $169.”*
**Today’s check:** RDDT is at $171, up 1% pre-market with the close-vs-open also positive. **This is exactly the absorption pattern we wanted to see** — flat and tight, no selling pressure, no extension. Per our R10.1 framework (multi-day-runner candidates often re-accelerate Day 4-6 after Day 1-3 profit-taking), this is the textbook entry zone.
**Trade construction:** Buy on first sign of volume re-acceleration today or tomorrow. Stop below the 5-day low. Target: a return to the post-earnings high of ~$185 in the next 2-4 weeks.
---
## What I’m watching but not buying
- **DAVE (Dave Inc)** — Reports earnings tonight. Currently flat pre-market. **The bar is high** (stock up 62% in the past month going into the print). This is the OPPOSITE of RDDT’s setup — RDDT was bombed-out, DAVE is extended. Wait for the AH reaction.
- **MNTN (MNTN Inc)** — Reports tonight AMC. Slight pre-market bid (+2.4%). Connected-TV ad platform with massive earnings inflection. Same wait-for-print logic.
- **OUST (Ouster)** — Reports tonight AMC. Up 6.6% pre-market continuing yesterday’s positioning. Yesterday it had a distribution day (+13% headline but down 6% from the open), so we’d been cautious. Tonight’s earnings determine the next leg.
---
## The broader watchlist (off-screener)
12 stocks from earnings reports earlier this and last week are in the **R10.1 second-entry window** today. Cleanest setups:
- **RDDT (Day 4)** — flat-zone forming, primary watch
- **SANM (Day 6, last day in window)** — flat & tight at $217
- **PRCH (Day 5)** — flat at $10.46
**One we’re dropping today:** PI (Impinj) — Day 5 fading on the regular session (down 2% pre-market with negative close-vs-open). The thesis is breaking. Skip.
---
## How to read this brief
- **STRONG (EP-β ≥ 70)** = high-conviction trade, volume confirmed, fundamentals clean
- **CANDIDATE (45-69)** = real signal but missing volume confirmation — wait or take smaller size
- **CAUTION (25-44)** = setup is iffy, skip unless you have a specific reason
The numerical scores (78, 91, 96) are our internal ranking. Higher = more conviction. 70+ is our STRONG threshold.
---
## Bottom line
**This is a position-day, not a chase-day.** Six STRONG signals across biotech, infrastructure, AI cloud, and consumer internet — but each gapping 17-35% pre-market means most of the easy money has been made overnight. The real question is whether each one holds the open.
**The R14.1 test (close-vs-open) is critical today.** A stock can close +20% on the day but be down -5% from the open — that’s distribution, not accumulation. We want to see positive close-vs-open into the bell on each of our six picks.
**If you’re going to do one trade today: VRDN.** Phase 3 wins are the clearest catalyst there is, and elegrobart’s path to FDA approval is now well-defined.
**If you want a setup that doesn’t require the opening volatility: RDDT Day 4 R10.1 entry.** Boring, but high-percentage.
Markets open at 9:30 AM ET. Stay disciplined on entries — these are good setups, but only if the stocks confirm by holding the gap.
---
*This is not investment advice. Markets are unpredictable. Always do your own research and never invest more than you can afford to lose.*